Jakob Loven
InvestorManaging Partner at Nextech Invest
Zurich, Switzerland
Writes $100K – $5M checks · typically $1.5M
Experience
- Juvia GroupCo-Founder and Managing Partnercurrent2025 — presentEurope
- Nextech Invest Ltd.Managing Partner2017 — 2025Zurich, Switzerland
- IDRxBoard Observer2022 — 2024Boston, MA
- Hexagon BioBoard Member2021 — 2024San Francisco Bay Area
- Flare TherapeuticsBoard Member2021 — 2024Boston, MA
- IconOVir BioBoard Member2021 — 2024San Diego, CA
- Breakthrough PropertiesAdvisory Board2020 — 2024Zurich, Switzerland
- Arrakis TherapeuticsBoard Member2019 — 2024Greater Boston
- A2 Biotherapeutics, Inc.Board Member2018 — 2024Los Angeles Metropolitan Area
- Boundless BioBoard Member2021 — 2024San Diego, CA
- Vividion Therapeutics. Inc.Board Member2019 — 2021Greater San Diego Area
- Kronos Bio, Inc.Board Member2019 — 2021San Mateo, California
- Kinnate Biopharma, Inc.Board Observer2019 — 2021San Diego, California, United States
- ArvinasBoard Member2018 — 2020New Haven, CT
- Turning Point TherapeuticsBoard Observer2018 — 2019Greater San Diego Area
- Autolus Ltd.Board Observer2017 — 2018London, United Kingdom
- Relay TherapeuticsCo-Founder2016 — 2017Greater Boston Area
- Third Rock VenturesSenior Investment Proffesional2015 — 2017Greater Boston Area
- Swedish American Chamber of Commerce - New EnglandSenior Adviser, SACC Life Science Acclerator2013 — 2016Greater Boston Area
- Syros PharmaceuticalsCo-Founder2013 — 2015Greater Boston Area
Education
- Karolinska InstitutetDoctor of Philosophy (Ph.D.), Medical Sciences2005 — 2010
- Anglia Ruskin UniversityBachelor's degree, Biomedical Sciences1999 — 2002
- Sigtunaskolan Humanistiska Läroverket (SSHL)International Baccalaureate, Natural Sciences1994 — 1996
Skills & more
Cell40Cell Biology80Molecular Biology52In Vitro13Genomics36Bioinformatics22Systems Biology11Lifesciences10Drug Discovery41Biotechnology19Biomarker Discovery2Epigenomics9
+12 more
TranscriptionCancer BiologyRNA biologyDrug DevelopmentMolecular OncologyEpigeneticsBiomarkersBiochemistryPharmaceutical IndustryChromatin ImmunoprecipitationSequencingHigh Throughput ScreeningLanguages English · French · Spanish · Swedish
From Jakob's professional profile.
Same school
Also attended Karolinska Institutet19
Andreas LindblomManaging Partner at ScietyGunnar AhlbergVenture Partner at ScietyJohan LundVenture Partner at ScietyJonathan IlickiInvestor at IndustrifondenKjersti FrognerInvestor at Almi InvestSarah KakadellisInvestor at SUPPLY CHANGE CAPITAL
+ 13 more
Also attended Anglia Ruskin University5
Also attended Sigtunaskolan Humanistiska Läroverket (SSHL)4
Shared employers
Also worked at Juvia Group1
Also worked at Nextech Invest Ltd.6
Also worked at Arrakis Therapeutics6
Alan WaltsVenture Partner at Advent Life SciencesRichard GasterManaging Partner at venBio PartnersNiresh BerinpanathanPrincipal at Nextech InvestFiona MacLaughlinVice President, Venture Investments at Johnson & Johnson Innovation – JJDCMichelle DoigPartner at Omega FundsChristopher O'DonnellPartner at Pfizer Venture Investments
Also worked at Relay Therapeutics9
Anneli MathesonExecutive Assistant at Prelude VenturesJulia PianSenior Associate at Atlas VentureEli CasdinChief Investment Officer and Founder at Casdin CapitalDeborah PalestrantPartner, Executive Chair, 4:59 Initiative at 5AM VenturesSteve KafkaGeneral Partner at S32Jaideep DudaniPrincipal at Monograph Capital Partners
+ 3 more
Colleagues at Nextech Invest
Alessia Jaeggli
Executive Assistant at Nextech Invest
Alexis Borisy
Chairman at Nextech Invest
Alfred Scheidegger
Managing Partner at Nextech Invest
Alice T. Shaw
Science Partner at Nextech Invest
Alina Levchuk
Head of Investor Relations at Nextech Invest
Amy Nelson
Executive Assistant at Nextech Invest
Antoni Ribas
Science Partner at Nextech Invest
Benjamin Cravatt
Science Partner at Nextech Invest
Network4
Arie Belldegrun
Founder and Senior Managing Director at Vida Ventures
Gabor Gyulveszi
Senior Associate at Nextech Invest
Thilo Schroeder
Managing Partner at Nextech Invest
Thomas Lips
General Partner at Nextech Invest
Investors connected to Jakob in public investor directories — a warm-intro map.






































